Please login to the form below

Not currently logged in
Email:
Password:

Chi-Med

This page shows the latest Chi-Med news and features for those working in and with pharma, biotech and healthcare.

Chi-Med cues up two more regulatory filings in cancer

Chi-Med cues up two more regulatory filings in cancer

Hong Kong biotech Chi-Med is on track to file one new cancer drug this year and another in the first half of 2020, as it reports initial sales for its ... Within two years, To expects Chi-Med to become “a fully integrated and globally-facing

Latest news

  • Chi-Med goes for third IPO in Hong Kong Chi-Med goes for third IPO in Hong Kong

    Chi-Med is 60.2% owned by conglomerate CK Hutchison, which will see its stake reduce to below 50% when the IPO goes through. ... The current pace of development of the biotech ecosystem in China is remarkable,” said Simon To, Chi-Med’s chairman.

  • Chi-Med and Lilly’s cancer drug Elunate a milestone for China Chi-Med and Lilly’s cancer drug Elunate a milestone for China

    Chi-Med is partnering with Eli-Lilly to commercialise the drug across China, where the two companies see a huge opportunity. ... Chi-Med's Simon To. “This launch is a major milestone for Chi-Med,” said Simon To, Chairman of Chi-Med.

  • Home-grown colorectal cancer drug approved in China Home-grown colorectal cancer drug approved in China

    Chi-Med's chairman Simon To. “Today’s approval is a major achievement for Chi-Med,” said Simon To, Chairman of Chi-Med. ... added, “This is the result of over a dozen years of steadfast commitment by Chi-Med in research and development in

  • AZ takes Chi-Med’s kidney cancer drug into phase III AZ takes Chi-Med’s kidney cancer drug into phase III

    a key milestone in Chi-Med's efforts to develop a range of oral cancer drugs for international markets. ... It is intended to support marketing applications for savolitinib in Europe and the US, according to Chi-Med.

  • Lilly enters cancer collaboration in China Lilly enters cancer collaboration in China

    Signs deal with Chi-Med to develop and commercialise fruquintinib. US-based pharma company Lilly has signed a deal with China's Chi-Med to develop and commercialise a treatment in ... Christian Hogg, CEO of Chi-Med did not go into details about the

More from news
Approximately 6 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Chinese biotech’s global ambitions Chinese biotech’s global ambitions

    It is among a handful of well financed, well organised companies captained by experienced pharma leaders which are now emerging from China – another example being Hong Kong-headquartered Chi-Med, which

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
EPG Health

REACH, ENGAGE & MEASURE HCPs ONLINE - Accomplish meaningful engagement via Medthority (www.medthority.com), a trusted independent medical website. Support the...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...